Barclays PLC Olema Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 94,915 shares of OLMA stock, worth $578,981. This represents 0.0% of its overall portfolio holdings.

Number of Shares

94,915

Previous 94,915 -0.0%

Holding current value

$578,981

Previous $1.13 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$10.41 - $16.46 $506,071 - $800,186	48,614 Added 105.0%	94,915 $1.13 Million
Q2 2024 Aug 14, 2024	BUY	$8.73 - $13.99 $30,476 - $48,839	3,491 Added 8.15%	46,301 $501,000
Q1 2024 May 15, 2024	SELL	$10.95 - $16.62 $6,416 - $9,739	-586 Reduced 1.35%	42,810 $484,000
Q4 2023 Feb 15, 2024	BUY	$10.53 - $17.14 $407,921 - $663,986	38,739 Added 831.84%	43,396 $609,000
Q3 2023 Nov 07, 2023	SELL	$8.19 - $12.98 $5,692 - $9,021	-695 Reduced 12.99%	4,657 $57,000
Q2 2023 Aug 03, 2023	BUY	$3.22 - $9.65 $2,350 - $7,044	730 Added 15.79%	5,352 $48,000
Q1 2023 May 04, 2023	BUY	$2.55 - $4.97 $1,820 - $3,548	714 Added 18.27%	4,622 $16,000
Q4 2022 Feb 13, 2023	SELL	$2.27 - $3.76 $3,788 - $6,275	-1,669 Reduced 29.93%	3,908 $9,000
Q3 2022 Nov 03, 2022	BUY	$2.72 - $5.88 $4,757 - $10,284	1,749 Added 45.69%	5,577 $16,000
Q2 2022 Aug 12, 2022	SELL	$2.04 - $4.61 $8,592 - $19,417	-4,212 Reduced 52.39%	3,828 $16,000
Q1 2022 May 16, 2022	BUY	$3.89 - $9.43 $31,275 - $75,817	8,040 New	8,040 $34,000

Others Institutions Holding OLMA

# of Institutions

136

Shares Held

58.7M

Call Options Held

141K

Put Options Held

23.1K

View Full List

About Olema Pharmaceuticals, Inc.

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $247M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

More about OLMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account